Evidence map›Paper›PMID 36788124›Full record

ArticlemAbs

TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.

Emma Davé, Oliver Durrant, Neha Dhami, Joanne Compson, Janice Broadbridge, Sophie Archer, Asher Maroof, Kevin Whale, Karelle Menochet, Pierre Bonnaillie and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Emma DavéEarly Solutions, UCB Biopharma UK, Slough, UK.
Oliver DurrantEarly Solutions, UCB Biopharma UK, Slough, UK.
Neha DhamiEarly Solutions, UCB Biopharma UK, Slough, UK.
Joanne CompsonEarly Solutions, UCB Biopharma UK, Slough, UK.
Janice BroadbridgeEarly Solutions, UCB Biopharma UK, Slough, UK.
Sophie ArcherEarly Solutions, UCB Biopharma UK, Slough, UK.
Asher MaroofEarly Solutions, UCB Biopharma UK, Slough, UK.
Kevin WhaleEarly Solutions, UCB Biopharma UK, Slough, UK.
Karelle MenochetEarly Solutions, UCB Biopharma UK, Slough, UK.
Pierre BonnaillieEarly Solutions, UCB Biopharma UK, Slough, UK.
Emily BarryEarly Solutions, UCB Biopharma UK, Slough, UK.
Gavin WildPV Supply and Technology Solutions, UCB Biopharma UK, Slough, UK.
Claude PeerboomPV Supply and Technology Solutions, UCB Biopharma SRL, Braine-l'Alleud, Belgium, EU.
Pallavi BhattaEarly Solutions, UCB Biopharma UK, Slough, UK.
Mark EllisEarly Solutions, UCB Biopharma UK, Slough, UK.
Matthew HinchliffeEarly Solutions, UCB Biopharma UK, Slough, UK.
David P HumphreysEarly Solutions, UCB Biopharma UK, Slough, UK.
Sam P HeywoodEarly Solutions, UCB Biopharma UK, Slough, UK.
Biopharma Technology (United Kingdom) · GBUCB Pharma (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long

Indexed as

Immunoglobulin Fc FragmentsImmunoglobulin FragmentsAnimalsHalf-LifeMammalsImmunoglobulin Fc FragmentsImmunoglobulin Fragmentsalbumin binderFc-freemonovalentmulti-specificmultivalent antigentargetingTrYbe®

Identifiers

PMID36788124
PMCPMC9937000
OpenAlexW4320856698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.